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A B S T R A C T
Molecular data are an essential component in the study of neoplasias. The important 
and incumbent role of molecular pathology in clinical practice is evident in the last 
classification of the World Health Organization (WHO) in 2008 for the tumors of the 
hematopoetic and lymphatic tissues, where incorporated are all the new molecular 
data and entities defined by genetic criteria. It is now recognized that a genetic ab-
normality can be considered diagnostic for an entity. At the same time the diagnostic 
approach of lymphoproliferative disorders is multifactorial; morphological, immuno-
histochemical and genetic characteristics, along with clinical data, are required for 
the diagnosis.
In the hematopathology laboratory, the molecular techniques used in every day prac-
tice regarding tissues are polymerase chain reaction (PCR) and in situ hybridization 
(ISH) using either a fluorescence chromogen (FISH) or plain chromogenic in situ 
hybridization (CISH). The usefulness of these molecular techniques in lymphopro-
liferative disorders is to document B- or T- cell clonality, including diagnosis of lym-
phoma, differential diagnosis between a reactive lymphoproliferation and lymphoma, 
staging, follow up, and detection of early stages of a lymphoma, and to detect genetic 
abnormalities, numerical or structural, diagnosis of certain lymphoma subtypes en-
compassing distinction of subtypes within the same entity with different biological 
behavior, prognostic indices, and indices of response to certain therapeutic regimens.
I N T R O D U C T I O N
Molecular biology is one of the fastest growing fields of basic research. This is due 
to the immediate extension implied by the understanding of the gene structure of cells 
and the capacity of relating certain genetic loci with certain entities.1
From the beginning, molecular technique results were so useful to pathologists 
RevIew
Hematopathology Department, 
Evagelismos Hospital, Athens, Greece
HOSPITAL CHRONICLES 2011, 6(4): 174–181
Correspondence to:
Maria Fameli-Pavlakis, MD, PhD, 
Hematopathology Department, 
Evagelismos Hospital, Athens, 
Greece. Τel.: +30-210-720-1542 / 
+30-210-720-1544 
E-mail: famelipavlaki@yahoo.gr
Manuscript received May 18, 2011; 
Revised manuscript received June 7, 
2011; Re-revised manuscript received 
September 2, 2011; Accepted September 
16, 2011
Key wORDS: lymphoma; polymerase 
chain reaction; in situ hybridization; 
fluorescence chromogen in situ 
hybridization; molecular biology
AbbreviAtions
ABL1 = V-abl Abelson murine leukemia 
viral oncogene homolog 1
ALK = anaplastic lymphoma kinase
BCL = B-cell lymphoma
CISH = chromogenic in situ hybridization
DLBCL = diffuse large B-cell lymphomas
DNA = deoxyribonucleic acid
FISH = fluorescence chromogen in situ 
hybridization
FL = follicular lymphoma
Hp = Helicobacter pylori
IGH= immunoglobulin heavy chain
ISH = in situ hybridization
MALT = mucosa-associated lymphoid 
tissue
MCL = mantle cell lymphoma
MYC = myelocytomatosis oncogene
MRD = minimal residual disease
NHL = non-Hodgkin lymphoma;
NPM-ALK = nucleophosmin-anaplastic 
lymphoma kinase
PCR = polymerase chain reaction
RNA = ribonucleic acid
WHO = World Health Organization
Conflict of Interest: The authors declare no conflict of interest.
TISSuE MOLECuLAR TECHNIquES IN LYMPHOPROLIFERATIVE DISORDERS
175
that these molecular tools were soon added to their diagnostic 
practice. Essentially, molecular pathology is a natural prolon-
gation both of classical pathology of macroscopic evaluation 
and morphologic evaluation by hematoxylin and eosin (H&E), 
as well as that of immunohistochemical approach.2 It is based 
on principles, techniques and tools of molecular biology that 
are applied in the clinical laboratory, transferring diagnos-
tic utilities to the cell’s nucleus and especially in its genetic 
material, deoxyribonucleic acid (DNA) and ribonucleic acid 
(RNA).3 The understanding of DNA structure has led to 
further studies and promotion of the idea of hybridization 
which is the core idea of all molecular techniques used in a 
clinical molecular laboratory. Especially in hematopathology, 
the use of molecular techniques is spreading rapidly due to the 
ability of biomarkers to determine molecular criteria for the 
diagnosis of certain entities, detect minimal residual disease 
(MRD) during staging or patient follow up, detect early stages 
or in situ lymphomas, improve prognostic certainty for patients 
with various lymphoma subtypes, investigate the interactions 
between neoplastic cells and their microenvironment, deter-
mine antigens, either genes, or functional pathways useful 
both for diagnosis as well as for the probable production of 
therapeutic targets (from gene to protein). One example is 
the discovery of nucleophosmin-anaplastic lymphoma kinase 
(NPM-ALK) translocation and the subsequent discovery in 
tissue of ALK-protein which is not only a biomarker of a cer-
tain lymphoma subtype (ALK+/ALK- lymphoma), but also 
an essential prognostic marker. Another example is the use 
of imatinib in the treatment of leukemia associated with the 
V-abl Abelson murine leukemia viral oncogene homolog 1, 
also known as ABL1, and other rearrangements where tyrosine 
kinase genes are implicated.
T I S S U e  M O L e C U L A R  T e C H N I Q U e S
Almost 80% of paraffin embedded tissue samples yield 
DNA suitable for PCR analysis. As a result, molecular tech-
niques on tissue samples are used with an increasing rate in 
everyday practice, and refer to polymerase chain reaction 
(PCR), in situ hybridization (ISH) using either a fluorescence 
chromogen (FISH) or plain chromogenic ISH (CISH).
Important advantages of these molecular techniques 
include the fact that they do not depend on cellular antigen 
expression and are characterized by high resolution: FISH 
x10-2, PCR 10-4 – 10-6 comparing to 5x10-2 of classical cytogenet-
ics. To choose one or both techniques depends on the desired 
outcome. For example, when the target gene is identified, PCR 
is the quickest, most sensitive and specific solution. When a 
cytogenetic abnormality is known, but the target gene is not 
identified completely, then the method of choice is FISH. 
Also, in the case of chromosomal translocations and complex 
rearrangements, PCR is not chosen, because a large number 
of primers are required.
P O Ly M e R A S e  C H A I N  R e A C T I O N  ( P C R )
Polymerase chain reaction (PCR) was developed in the 
mid 80’s in California, and today is a “mature” technique with 
broad applications in the laboratories due to its high capacity in 
detecting certain genetic targets. It is a reaction that multiplies 
nucleic acid via DNA polymerase, hence its name. The basic 
principles are illustrated in Figure 1. A certain DNA sequence 
is selected (oncogenes, genetic mutations, etc) and with the 
use of short DNA sequences, called primers, and DNA poly-
merase, the selected target is amplified according to 3 steps, 
denaturation, annealing, and extension. These 3 steps define a 
PCR cycle which accelerates with fluctuation of temperature. 
The repetition of these cycles leads to the production of many 
copies of the target sequence, to the point that after 30-40 
cycles more than 1X109 copies are made. The PCR product is 
then analyzed and visualized either in the form of bands using 
the heteroduplex technique or in the form of peaks using gene 
scanning. The whole procedure lasts 2-4 hours and today is 
fully automated using special machines called thermal cyclers.
There are several types of PCR: simple PCR, nested PCR, 
seminested PCR, reverse transcriptase PCR, real time PCR. 
The use of PCR spread rapidly among laboratories due to its 
advantages, which include high sensitivity and specificity, auto-
mation, capability of simultaneous study of multiple samples, 
rapid completion and capability of using archived material. 
Basic disadvantages of this methodology include destruction of 
cell morphology, existence of false negative results due to bad 
quality or limited DNA, improper annealing of PCR primers, 
etc., or false positive results due to contamination, selective 
amplification of other genetic regions, etc. Key factors which 
affect PCR specificity and sensitivity include suitable prim-
ers (complementary to the target DNA), precise compliance 
with each protocol, quality of DNA polymerase, avoidance of 
FIgURe 1. Principle for detecting monoclonal B-cell popula-
tions on tissue sections.
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contaminations, quality of tissue sample (means of fixation, 
adequate sample). The fact that in PCR, cell morphology is 
not preserved, make necessary a high experience in result 
evaluation. A reliable evaluation requires a simultaneous 
use of controls (positive, negative, nonspecific), specialized 
personnel, collaboration of the molecular biologist with the 
pathologist, awareness of the procedure by the medical doctor 
(about technique, tissue limitations, false positive and false 
negative results) and the essential knowledge that clonality is 
not equivalent to malignancy.
I N  S I T U  H y B R I D I z A T I O N  ( I S H )
In situ hybridization (ISH) is a method of direct visualiza-
tion of selected genetic targets (signal amplification methods) 
and is relying on the fundamental property of nucleic acids 
(due to the principles of complementarity of bases) to form 
stable dimers called hybrids. Visualization is achieved with 
fluorescent DNA or RNA probes (fluoresence ISH- FISH) 
or immune-chromogen probes (chromogenic ISH-CISH), 
and the signals can be amplified and processed with specific 
software. The procedure includes consecutive steps of dena-
turation and annealing with the probes being applied directly 
on the glass slide. The emitted visual signals are verified by 
microscopy (light or fluorescent) and further analysis can be 
made via specific software.
There are several types of ISH. In chromogenic ISH 
(CISH), the probe is tagged to a non fluorescent chromogen. 
There is no need for a fluorescence microscope for visualiza-
tion and since the signal never fades, the slides can be kept in 
archive for long periods of time. In fluorescence ISH (FISH), 
the probe is tagged directly with fluorophores. In dual color 
FISH (dFISH), there is simultaneous use of two probes which 
emit at different wave length. Therefore, each probe emits a 
different color (split signal) and when they fuse they emit a 
third color (fusion signal) (Fig. 2) like in the case of breakpoint 
cluster region (BCR) Abelson murine leukemia viral oncogene 
homolog (ABL) (BCR-ABL). More recent techniques still 
in research for the time being, are the spectral karyotyping 
(SKY), the multiplex FISH (M-FISH), whereby multiple 
fluorophores are used with image analysis software to visual-
ize all chromosomes, and comparative genomic hybridization 
(CGH), a variation of FISH which can detect very small addi-
tions or deletions of genetic material.
The key for the successful outcome of the procedure is 
the correct probe. There are probes for the detection/study 
of whole chromosomes, chromosome fragments, or specific 
genetic locus (centromeres, telomeres, etc.).
In situ hybridization is a very useful technique with many 
advantages. It is a quick and easy methodology which conserves 
cell or tissue morphology achieving correlation of molecular 
hybridization and tissue morphology. It can be applied on 
non dividing cells also with the capability for utilization of 
two probes in the same tissue section. It permits increased 
resolution for the identification of specific abnormalities 
(especially when combined with classical cytogenetics) and 
can highly improve diagnostic ability (for example by using 
a probe for the target gene and a centromeric probe) and it 
discriminates the true genetic amplification or deletion from 
chromosomal aneuploidy.
Other promising techniques are the tissue microarrays 
(TMA), the comparative genomic hybridization (CGH), etc. 
Although these techniques handle a vast amount of data, they 
constitute, at least for the time being, a database.
C L I N I C A L  A P P L I C A T I O N S  
O F  M O L e C U L A R  T e C H N I Q U e S  
I N  H e M A T O P A T H O L O g y
Hematopathology is a field where molecular techniques 
and their applications in everyday practice found a suitable 
ground for deployment. Molecular techniques4 are currently 
applied for diagnosis, differential diagnosis, prognosis, predic-
tion, targeted therapies and follow up. On clinical grounds 
these applications can be divided into three main categories 
(Table 1), detection of Β and/or Τ-cell clonality, detection of 
chromosomal aberrations (structural or numerical) and detec-
tion of viral genomic material.
Selectively, a small number of the most recent molecular 
data on common lymphoproliferative disorders with clinical 
impact will be described below.
FIgURe 2. FISH analysis for detection of translocations char-
acteristic of Follicular and Mantle cell Lymphoma respectively 
(pictures from the files of Hematopathology Dpt).
TISSuE MOLECuLAR TECHNIquES IN LYMPHOPROLIFERATIVE DISORDERS
177
D I F F U S e  L A R g e  B - C e L L  Ly M P H O M A S  ( D L B C L) 
/  w H O  I C D - O  9 6 8 0 / 3
They were the first group of lymphomas where the molecu-
lar derivations were directly related to differential diagnosis 
and clinical behavior, divided into three distinct subtypes, the 
germinal center B-cell (GCB) DLBCL, the activated B-cell 
(ABC) DLBCL, and the primary mediastinal DLBCL.
These subgroups have distinct molecular characteristics, 
different oncogenetic pathways and different clinical course.5-11 
It is widely accepted that the existence of chromosomal abnor-
malities in DLBCL are directly correlated with clinical course. 
Cases that carry gene rearrangements for B-cell lymphoma 
(BCL) 2, BCL6, myelocytomatosis oncogene (MYC), BCL10 
genes have statistically poorer prognosis than cases which 
share similar histological characteristics, but lack detect-
able gene rearrangements.12 Also, DLBCL with particular 
numerical chromosomal abnormalities (i.e. a distinct genetic 
signature), are characterized by poor prognosis even after 
immunochemotherapy.13
P L A S M A B L A S T I C  L y M P H O M A / w H O  I C D - O  9 7 3 5 / 3
This aggressive type of lymphoma has frequent immu-
TABLe 1. Clinical Applications of Tissue Molecular Methodologies.
Tissue Molecular 
Study Method Applications in Clinical Practice examples
B/T cell clonality 
detection
PCR Differential diagnosis between 
reactive lesions and lymphoma 
Lymphoma / reactive lymphadenopathy
MALT-NHL / Hp gastritis
Cutaneous T-cell lymphoma / reactive T-cell hyperplasia
Molecular diagnosis of lymphoma Double hit lymphoma,
ΕBV+ lymphoma of the elderly,
Pediatric follicular lymphoma
Diagnosis of in situ lymphoma In situ follicular lymphoma (FL),
In situ mantle cell lymphoma (MCL)
Detection of early lesions Early mycosis fungoides
Staging Documentation of discordant lymphomas
Detection documentation of minimal residual disease (MRD) 
in bone marrow 
Documentation of clonal identity 
at different anatomical sites either 
simultaneously, or during relapse
Extranodal MALT lymphomas have a higher incidence of 
infiltration (simultaneous or subsequent) in many extranodal 
sites (gastrointestinal tract, lung, etc.). PCR detects the 
identity of the B-clone in all the infiltrated sites 
Investigation for early relapse. Early (molecular) relapse
Detection of 
translocations
PCR, FISH Documentation of lymphoma 
subtypes
Detection of chromosomal translocations for diagnosis of FL 
or MCL
Prognostic markers Detection of MYC in DLBCL 
Therapeutic decisions DLBCL,
Detection of t(11;18) translocation in gastric MALT lymphoma
Virus detection CISH Documentation of new entities EBV+ lymphoma of the elderly
Prognostic value EBV+ lymphoma of the elderly 
Follow up of 
therapeutic 
regimens
PCR, FISH Investigation for molecular  
remission
The achievement of molecular remission is an independent 
prognostic factor both for MCL and FL
Detection of t(11;18) translocation is a more sensitive marker 
than B-cell clonality in patient follow up for gastric MALT 
lymphoma.
CISH = chromogen in situ hybridization; DLBCL = diffuse large B-cell lymphoma; EBV = Epstein-Barr virus; FISH = fluorescence in situ 
hybridization; FL= follicular lymphoma; Hp = Helicobacter pylori; MALT = mucosa-associated lymphoid tissue; MCL = mantle cell lymphoma; 
MRD = minimal residual disease; MYC = myelocytomatosis oncogene; NHL = non-Hodgkin lymphoma; PCR = polymerase chain reaction;
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noglobulin heavy chain (IGH) / MYC translocations and 
additional genetic material in various chromosomal loci. The 
activations of the MYC locus is an important step in the patho-
genetic mechanism and seems to be related to Epstein-Barr 
virus (EBV) infection.14
S U B T y P I N g  L y M P H O M A S
Certain chromosomal translocations are closely related 
or unique to specific lymphoma types and considered as their 
molecular identity (Fig. 2). There follow some illustrative 
examples.
F O L L I C U L A R  Ly M P H O M A  /  w H O  I C D - O  9 6 9 0 / 3
Translocation t(14;18)(q32;q21) IGH/BCL2 is an essential 
element of follicular lymphoma diagnosis. It is considered to 
be the initial step in lymphomagenesis, however a second event 
(second hit) is necessary for this to happen (additions, dele-
tions of genetic loci). Molecular studies in follicular lymphoma 
have shown complex interactions between follicular lymphoma 
cells and their microenvironment (surrounding immunologic 
network), directly implicated in the course of the disease.2,15
M A N T L e  C e L L  Ly M P H O M A  /  w H O  I C D - O  9 6 7 3 / 3
Translocation t(11;14)(q13;q32) IGH/BCL1 is the key 
component in the diagnosis of mantle cell lymphoma, an 
aggressive lymphoma with a rather non aggressive histologic 
appearance.
Ι N  S I T U  L Y M P H O M A S
The 2008 World Health Organization (WHO) classifica-
tion of lymphomas first recognized the existence of in situ 
lymphomas, at least for follicular and mantle cell lymphomas. 
Molecular methodologies on whole tissue samples, often as-
sociated with laser capsule microdissection technology, are 
essential not only for the documentation of the diagnosis, but 
for follow up studies as well. Current data strongly suggest an 
indolent biological behavior of in situ lymphomas. Neverthe-
less, more data are still necessary for this patient group, since 
available information is still limited.2,16
C U T A N e O U S  L y M P H O M A S
Cutaneous lymphoproliferative disorders of either B- or 
T- cell origin are among the most common cases with border-
line clinical and histological features between a malignant and 
reactive process. Severe reactive cutaneous lymphoprolifera-
tions mimicking lymphoma are usually the result of drugs, 
autoimmune disorders or other factors. Documentation of 
B- or T-cell clonality is a strong indicator of neoplasia and 
it is also capable to detect very early lymphomatous lesions 
(Fig. 3, Table 1).2,17
T H e  C O N C e P T  O F  M O L e C U L A R  D I S e A S e 
/  M O L e C U L A R  R e M I S S I O N
The detection of molecular disease in the bone marrow 
during the staging of a patient with follicular lymphoma 
is considered a negative prognostic factor18 and a sign of 
increased risk for relapse (Fig. 4).19 Molecular disease may 
persist, despite clinical and histological remission. Nowadays 
it is widely accepted that molecular remission constitutes an 
independent prognostic factor, at least for some lymphoma 
types. For example molecular depression is now an independ-
FIgURe 3. Gel electrophoresis of PCR products. Differential 
diagnosis between polyclonal (reactive) and monoclonal (lym-
phoma) process (pictures from the files of Hematopathology 
Dpt).
FIgURe 4. Documentation of B-cell clonality on bone marrow 
trephine during staging procedure for gasric Diffuse Large B-
cell Lymphoma (pictures from the files of Hematopathology 
Dpt).
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ent prognostic factor for patients with mantle cell lymphoma 
after immunochemotherapy.20 Finally, molecular clones can 
be used as markers for the evaluation of therapeutic results 
or the detection of early recurrences.
M O L e C U L A R  D I A g N O S I S
Some new entities are now included in the 2008 WHO 
classification, that require molecular criteria to be established. 
Certain examples are detailed below.
D O U B L e  H I T  Ly M P H O M A S
They constitute a unique subgroup of the main group of 
“B-cell lymphomas, unclassifiable, with features intermediate 
between diffuse large B-cell lymphoma and Burkitt lymphoma” 
(WHO 2008) and they are characterized by concurrent IGH-
BCL2 and MYC rearrangements. In fact there are no histo-
logical or immunohistochemical criteria to differentiate this 
subgroup. Essentially, this category can be distinguished only 
by molecular characteristics (FISH) and it is associated with 
very poor prognosis, resistance to therapy and particularly ag-
gressive behavior. Because of these certain pertinent clinical 
data, today it is imperative that all DLBCL should be tested 
for MYC translocation, or other chromosomal aberrations.2,21,22
e P S T e I N - B A R R  v I R U S  ( e B v )  P O S I T I v e  D L B C L 
O F  T H e  e L D e R Ly
This is a new subtype of DLBCL, with EBV positivity in 
up to 90% of the neoplastic cells (CISH technique) and it is 
believed to be related to immunological abnormalities (a part 
of aging process). They have a very aggressive clinical course, 
with median survival of 2 years.2,23
P e D I A T R I C  F O L L I C U L A R  Ly M P H O M A
Severe reactive lymphadenopathy is a common finding 
in children and shares certain features on histological level. 
Pediatric follicular lymphoma is a new subtype among follicular 
lymphoma types, that closely resembles a reactive process, 
both morphologically and immunophenotypically. Key role 
in the diagnosis of lymphoma process is the detection of im-
munoglobulin rearrangements by PCR.2
A N A P L A S T I C  L A R g e  C e L L  Ly M P H O M A  ( A L C L)
Anaplastic lymphoma kinase (ALK) positive, ALK nega-
tive or variant translocations involving the ALK gene or other 
partner genes can be present in this type of lymphoma, but 
the most frequent is translocation t(2;5)(p23;q35). The pres-
ence of ALK translocations indicates a favorable prognosis 
compared with cases devoid of ALK translocations. Overall 
5-year survival rate is 80% in ALK positive cases and 48% in 
ALK negative cases. Immunostaining of the ALK with the use 
of monoclonal antibodies has largely replaced molecular tests 
and is a characteristic example of the evolution of knowledge 
from gene to protein level (ALK positive ALCL /ICD-O 
9714/3, ALK negative ALCL /ICD-O 9702/3).2
T - C e L L  L y M P H O M A
quite often it is necessary to search for possible rearrange-
ments of the T-cell receptor with PCR, to distinguish between 
excessive/reactive T-cell hyperplasia and T-cell lymphoma, 
especially in skin lesions. Detection of certain chromosomal 
abnormalities (structural or numerical) with FISH (defining 
molecular signature) allows the enhancement of diagnostic and 
prognostic practice and defines possible therapeutic targets 
[example t(2;5) and t(5;9) for anaplastic T-cell lymphoma and 
peripheral T-cell lymphoma, not otherwise specified (NOS) 
respectively24-27].
H O D g K I N  L y M P H O M A
Recent studies with quantitative reverse transcription PCR 
(RT-PCR) have managed to determine a group of 11 genes, 
4 of which concern functional pathways (cell cycle, apoptosis 
etc.). These genes are capable of separating stage IV patients 
into groups of high and low risk giving statistically significant 
percentages of 5-year survival free of disease.28
g A S T R I C  M A L T  L y M P H O M A  /  w H O 
I C D - O  9 6 9 9 / 3
Primary gastric lymphoma of mucosa-associated lymphoid 
tissue (MALT) type is an indolent lymphoma, with close rela-
tionship to pre-existing Helicobacter pylori (Hp) gastritis. It is 
often impossible to distinguish MALT lymphoma from severe 
gastritis both with morphology and immunohistochemistry. In 
such cases careful application of molecular techniques can be 
very helpful. Detection of B-cell clonality by PCR in a gastric 
biopsy suspicious, but not diagnostic, of lymphoma strongly 
supports a lymphoma diagnosis. It is well known that approxi-
mately 22% of gastritis samples (grade 3 and 4) may harbor 
monoclonal B- cell clones and that in biopsies of patients with 
Hp- gastritis which developed into MALT lymphoma, B-cell 
clonality was detected years before the diagnosis of MALT 
lymphoma (up to 1-2 years) and it is compatible with very early 
stages of the disease.29-31 Thus, in borderline cases, a careful 
evaluation of histological, immunophenotypical and molecular 
criteria is crucial to establish a definite diagnosis.31,32
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w H A T  I S  T H e  S I g N I F I C A N C e  O F 
B - C e L L  C L O N A L I T y  I N  P O S T -
T R e A T M e N T  g A S T R I C  B I O P S I e S ?
In approximately 50% of gastric MALT lymphoma cases, 
B-cell monoclonality persists after the attainment of complete 
response, although in some patients the clonal population 
gradually disappears (delayed remission).33 In some studies 
patients with remission, but with persistent monoclonality were 
significantly more likely to relapse,34 however, other studies 
have failed to confirm an association.35
D e T e C T I O N  O F  T R A N S L O C A T I O N 
T ( 1 1 ; 1 8 )
MALT lymphomas can be associated with certain chromo-
somal abnormalities, both structural and numerical.31 MALT 
lymphomas with chromosomal abnormalities have different 
pathogenetic pathways and as a result, different biologic 
behavior.36
Translocation t(11;18)(q21;q21)-API-2/MALT-1 is the 
most common chromosomal aberration, being found in ap-
proximately 25% of gastric MALT lymphoma cases. MALT 
lymphomas carrying this translocation do not have any histo-
logic or immunophenotypic feature different from transloca-
tion negative cases. Nevertheless they are characterized by 
advanced disease stage, they have more often spread beyond 
the stomach and the patients are Hp-negative. Cases which 
present t(11;18) are strongly associated with failure to regress 
after Hp eradication (all stages) and they have worse response 
to treatment with oral alkylating agents, but not to rituximab 
or cladribine. In addition, translocation positive tumors are 
paradoxically less likely to transform into DLBCL, and they 
have different gene expression profile as well as different 
pathogenetic mechanism.31,32 Finally, t(11;18) is a more sensi-
tive marker than B-cell clonality for the monitoring of residual 
molecular disease.37,38
P e R S P e C T I v e
Gene expression profiling techniques are not yet avail-
able for everyday practice in clinical laboratories. Neverthe-
less, gene expression profiling gives the ability to investigate 
changes in the expression of thousands of genes within a 
single cell. This technique will promote identification of novel 
subtypes within known lymphoma categories, new prognostic 
groups, as well as new insights in the pathogenetic and clinical 
contributions of infiltrating nonmalignant cells.
The knowledge and application of molecular techniques 
into the clinical laboratory is no longer a luxury; on the con-
trary, it is an essential and mandatory tool for the proper han-
dling of patients with regard to diagnosis, prognosis and follow 
up. Identification of putative pathogenic agents or relatedness 
to other known agents and thus close to causation of disease.
Besides, the new classification of WHO includes molecu-
lar parameters, especially in lymphomas, a broad group of 
heterogenic malignancies with different biological and clini-
cal behavior. Molecular pathology’s aim is the detection of 
biomarkers of functional signature. This fact does not only 
concern the determination of diagnostic and prognostic fac-
tors, but also the early detection of high risk patients as well as 
the reevaluation of patients after treatment. Finally, molecular 
methodologies can be an opportunity, as well as a challenge 
to define possible targets for future therapeutic strategies, or 
to develop a therapy-oriented classification.
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